mTOR inhibitor
Everolimus + Letrozole for Endometrial Cancer
Recruiting1 awardPhase 2
Morristown, New Jersey
This trial will test if a combination of everolimus and letrozole can help control endometrial cancer that has come back or is progressing. The safety of this drug combination will also be studied.
mTOR Inhibitor
RAD001 +4 More for Breast Cancer
Recruiting3 awardsPhase 2
Houston, Texas
The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies given on this study more effective. Primary Objective · To determine if the addition of an mTOR inhibitor to standard neoadjuvant chemotherapy in patients with triple receptor-negative breast cancer causes molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway. Secondary Objectives * To evaluate pathologic complete response (pCR) rates for each treatment group. * To evaluate the relationship between pCR and the molecular changes (inhibition/activation) of the PI13K/PTEN/AKT pathway in each treatment group. * To evaluate overall response rates (ORR) for each treatment group. * To assess the toxicity of both regimens and to evaluate the relationship of toxicities with PI3K/PTEN/AKT pathway status.
Kinase Inhibitor
Ceritinib + Everolimus for Lung Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dosage of ceritinib and everolimus for treating patients with solid tumors that have spread from the original site. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
mTOR inhibitor
Everolimus + Letrozole for Ovarian Cancer
Recruiting3 awardsPhase 2
Baltimore, Maryland
This trial is testing a combination of two drugs, Everolimus and Letrozole, to treat women with specific types of recurrent or persistent cancers. Everolimus stops cancer cells from growing, and Letrozole reduces hormones that some cancers need to grow.
Popular Filters
Phase 3 Trials
mTOR inhibitor
Long-Term Safety of Everolimus for Tuberous Sclerosis
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is for patients with TSC and refractory seizures who are currently receiving everolimus treatment and are determined to be benefiting from it, in order to evaluate the long-term safety of the treatment.
Immunosuppressant
Tacrolimus + Everolimus vs. Tacrolimus + MMF for Heart Transplant Care
Recruiting4 awardsPhase 3
Birmingham, Alabama
This trial will compare two different treatments for kids who have had a heart transplant, to see which one is better at reducing the risk of problems like coronary artery disease, kidney disease, and rejection of the transplant.
Trials With No Placebo
Kinase Inhibitor
Vandetanib + Everolimus for Advanced Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of two drugs when given together to treat patients with cancer that has spread. The drugs may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.